amesit.wordpress.com
Most Southlands stores reopened at noon although “some retailers and restaurants may still remain closed,” the shoppinyg center said on its website. Cleanup and damage checka have been under way atthe 1.7 million-square-foot retai l complex since Sunday, when a tornado touchex down nearby at 1:49 p.m. The twister caused moderater damageat Southlands, located at E-470 and Smokh Hill Road. Rooftop heating, venting and air-conditioningg units were damaged, windows were broken, and a car was Natural gas leaks alsowere noted, and authoritiews shut down gas service for a Southlands, which opened in 2006, is the Denvee area’s largest shopping center by retailo space.
It consists of several freestanding buildingzs connected by pedestrian corridorsand streets. The comples is owned by Granite Southlandsw Town Center LLC and managed by Forest City CommercialManagemen Inc. Four other tornadoes were spotted north and east of DenverSundayy afternoon, and large hail struco some areas. As many as 3,000 Xcel Energh customers were without power for a time in parts of Aurorwand Centennial.
Monday, October 31, 2011
Saturday, October 29, 2011
Let's Value People as an Asset, and Bring Financial Statements into the 21st ... - Huffington Post (blog)
http://auto-site.biz/?f=4&n=2
Let's Value People as an Asset, and Bring Financial Statements into the 21st ... Huffington Post (blog) Intangible assets -- patents, intellectual property, brands, and research & development -- are » |
Wednesday, October 26, 2011
Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary Endpoints Associated with Cardiovascular Risk
loxezop.wordpress.com
Previously announced BLOOM data demonstrated that lorcaserin was highly achieving statistical significance on allthrewe co-primary efficacy endpoints, and was very well tolerated. The BLOOnM results also satisfy the efficacy requirement in the most recenft US Food andDrug Administration, or FDA, drafrt guidance for the development of drugs for weightg management. "These data provide reason for new optimism for the millionsx of people who struggle with managing theidr weight and are in needof novel, well tolerates treatments to help improve their overall health," said Steven R. Smithh , M.D.
, Co-Principal Investigator and Professor and Assistant Director for Clinical Research at the Penningtonm BiomedicalResearch Center. "Lorcaserin's positive impact on multipl secondary measures has important implications forimprovinh co-morbidities associated with excess weight and furthere demonstrates the medically significant benefits of 5% or more weigh loss, a mark two-thirds of the lorcaserin patient s who completed the BLOOM trial achieved." "Given the positivre lorcaserin BLOOM results, we are focused on partnering effortsx and realizing lorcaserin's significant commercial potential," stated Jack Lief, Arena's Presidenyt and Chief Executive Officer.
In addition to supporting the previously announcex results on allthree co-primart endpoints on an last observation carried forward basis, the data presenter today demonstrated strong efficacy in patients who completed one year of treatmen according to the trial's protocol. In the per protocol nearly two-thirds (66.4%) of lorcaserin patients lost atleast 5% of theidr weight compared to 32.1% of patients on placebo and over one-third (36.2%) of lorcaserin patientss lost at least 10% of their weight comparexd to 13.6% for placebo (p<0.0001). The averag e weight loss in this populationwas 17.9 pounds in the lorcaserih group, compared to 7.4 pound s in the placebo group.
Patients randomized to remain on lorcaseri for Year 2 maintained a significantly greater amount of weight loss compared to the lorcaserib patients who switched to placeb at Week 52 in boththe ITT-LOCc and per protocol populations. New data demonstrate that treatmentf with lorcaserin over one year was associated with highlg significant improvements compared to placebo in multiple secondary endpoints associated withcardiovascular risk, -- Blood Pressure: systolic blood pressure, diastolic blood pressurs and heart rate -- Lipids: total cholesterol, LDL cholesteropl and triglycerides -- Glycemic fasting glucose, fasting insulin and insulin resistance -- Inflammator Markers of Cardiovascular high-sensitivity CRP and fibrinogen Qualitg of Life, as assessed by the Impact of Weightg Questionnaire - Lite, also improves to a significantly greater extent in the lorcaserin group than the placebo group at Week 52.
"We are please to present the BLOOM data in a scientific Inthis trial, lorcaserin helped patients rapidly lose weight and keep it off in a well-tolerateds manner," said William R. Shanahan , M.D., Arena's Vice President and Chierf Medical Officer. "We believed that lorcaserin's overall safety profile along with the significantt improvements seen in important secondary endpointsx associated with cardiovascular risk will be supportives of the approval We look forward to announcinv our BLOSSOM data in September and completing our NDA submissiom by the end ofthe year.
" Lorcaseri was very well Discontinuation rates for adverse events were similar in the lorcaserihn and placebo groups for Year 1 and Year 2 (7.1 vs. 6.7% and 3.0% vs. 3.0%, respectively). In additiob to the previously announcedtolerability data, today's presentation also reportede that lorcaserin demonstrated no increase in depressionb or suicidal ideation compared to placebo. Depression adverse events were measured using a Standard MedDRA Query for adverse eventt terms related todepression depression, depressed mood, crying, decreased interest, Overall, the rate of depression-relatef events was low and ratew were comparable in patients who took lorcaserin and Suicidal ideation was prospectively evaluated by administration of the Beck Depressionj Inventory-II.
Overall, the rate of suicidak ideation was low and simila numbers of patients on lorcaserin and placeboi reported suicidal thoughts during Year 1 andYear 2. Usinfg an LOCF analysis for each year, the assessment of echocardiogramds performed at baseline and aftert patientscompleted 6, 12, 18 and 24 monthsw of dosing indicated that lorcaserin was not associatexd with valvular insufficiency: during two years of use, rateas of change in individual regurgitang scores and the development of FDA-defined valvulopathh (moderate or greater mitral insufficiency and/or mild or greater aorti insufficiency) were similar between treatment Lorcaserin met the primary safety endpoint of no significant difference in ratesw of valvulopathy at 12 months.
Rates of valvulopathyg at 6, 12, 18 and 24 monthsd for lorcaserin versus placebowere 2.1% vs. 1.9% (p=0.88), 2.7% vs. 2.3% 2.9% vs. 3.1% (p=0.86) and 2.6% vs. 2.7% At 18 and 24 months, rates of valvulopathyh for lorcaserin patients crossing over to placeblwere 3.6% and 1.9%, respectively. In addition, similare numbers of mitral insufficiency shiftw and aortic insufficiency shifts in Year 1 and Year 2 were reportec for patients on lorcaserinand placebo. The FDA previously requested that Arena rule outa 1.5-fold or greaterd risk of valvulopathy with 80% power.
Assuminb similar results in Arena's final pivotal trial, BLOSSOM (Behavioral modification and LOrcaserin Second Study forObesityh Management), the integrated data set from the two trialsa will be more than sufficientlt large to meet this requirement. BLOOM, the first of three lorcaserin Phase3 trials, is a randomized, placebo-controlled trial involvinh 3,182 patients in approximately 100 sites in the US. The triap evaluated 10 mg of lorcaserin dosefd twice daily versus placebo overa two-year treatment periods in obese patients (Body Mass Index, or BMI, 30 to 45) with or without co-morbid conditions and overweight patients (BMI 27 to less than 30) with at leastt one co-morbid condition.
The triall did not include any dose titrationor run-in period. Patients were randomized in a 1:1 ratiio to lorcaserin or placeboat baseline. At Week 52, 856 patienta taking lorcaserinwere re-randomized in a 2:1 ratio to continus lorcaserin or to switch to placebo, and 697 patients on placebop were continued on placebo. Patients received echocardiogramsat screening, and at 6, 12, 18 and 24 months after initiating dosing in the patients with FDA-defined valvulopathy were excludeds from enrolling in the trial.
The Phased 3 program consists ofthree trials, BLOOM, BLOSSOM and BLOOM-DMM (Behavioral modification and Lorcaserin for Overweight and Obesith Management in Diabetes Mellitus), and is plannerd to enroll a total of approximately 7,800 patients. BLOOM and BLOSSOM comprise the Phase 3 pivotaplregistration program. BLOSSOM has enrolled 4,008 patients and is evaluating 10 mg of lorcaserin dosed once or twicw daily versus placebo overa one-year treatment period in obese patients with or withoutr co-morbid conditions and overweight patients with at least one co-morbid condition at abou 100 sites in the US.
BLOOM-DMM is expected to completwe enrollment around the end of June and is evaluatingv 10 mg of lorcaserin dosedr once or twice daily versuse placebo overa one-year treatment period in obese and overweightr patients with type 2 diabetes at about 60 sites in the US. Approximatelty 600 patients are expected to be enrolled in which is planned as a supplement to thelorcaserin NDA. A standardizecd program of moderate diet and exerciswe guidance is included in the Phase3 program.
The program's hierarchicall y ordered co-primary efficacy endpoints are: the proportion of patient achieving 5% or greater weight loss aftere12 months, the difference in mean weight loss compared to placebo after 12 months, and the proportioh of patients achieving 10% or greater weightg loss after 12 months. Arena is also studyintg several keysecondary endpoints, including changes in seru m lipids, markers of inflammation and insulib resistance, and in the BLOOM-D trial, other indicators of glycemic control. In BLOSSOMk and BLOOM-DM all patients will receive echocardiogramzsat baseline, at month 6, and at the end of the studt to assess heart valve function over time.
In contrastf to the BLOOM trial, however, there are no echocardiographicf exclusion criteria for entry into thes trials and there is no monitoring by anindependent board. Lorcaserin is a noveol single agent that represents the first in a new class of selective serotonin 2Creceptor agonists. The serotonin 2C receptot is located in areas of the brainh involved in the control of appetiteand metabolism, such as the Stimulation of this receptor is strongly associatesd with feeding behavior and satiety.
Lorcaserin is currently being evaluates in a Phase 3 program expected to enrololapproximately 7,800 patients and potentially represents a targeteed treatment option for the millions of patients who need to bettere manage their weight. Arena has patents that cover lorcaserin in the US andothef jurisdictions, which in most cases are capable of continuingf into 2023 without taking into account any patenrt term extensions or other exclusivity Arenq might obtain. The National Institutes of Health reported in 2007 thatabout 65% of US adultxs are overweight or obese.
Medical and related costs of obesity to the USare $123 billion per year accordintg to a 2005 report by the Internationa l Diabetes Federation. Studies have shownm that weight lossof 5% to 10% is medically significanty and results in meaningful improvementw in cardiovascular risk factors and a significant reductionm in the incidence of type 2 diabetes. Diet and exercise should form the basis of healthy weight but pharmaceutical treatment options for obesity are currentlg limited for the many patientw that require additional help in achieving and maintaining medically importantweigh loss.
The FDA draft guidance document for developing products for weighyt management dated February 2007 provides recommendations regarding the development of druges for the indication of weight It contains two alternate efficacy only one of which needs to be metfor approval. The guidancw provides that, in general, a producr can be considered effective for weight management if afterf one year of treatment either of thefollowing occurs: (1) the difference in mean weight loss between the active-product and placebo-treaterd groups is at least 5% and the differenced is statistically significant, or (2) the proportion of subjecte who lose greater than or equal to 5% of baselined body weight in the active-product group is at least 35%, is approximately double the proportiobn in the placebo-treated group, and the difference betweemn groups is statistically significant.
Arena is a clinical-stage biopharmaceutical company focusedon discovering, developing and commercializinf oral drugs in four major therapeutic areas: central nervous system, inflammatory and metabolixc diseases. Arena's most advanced drug candidate, lorcaserin, is being investigated in a Phasse 3 clinical trial program forweight Arena's broad pipeline of novel compounda target G protein-coupled receptors, an important class of validated drug and includes compounds being evaluated independently and with including Merck & Co., Inc., and Ortho-McNeil-Janssemn Pharmaceuticals, Inc. Arena Pharmaceuticals(R) and Arena(R) are registered service marks ofthe company.
"APD" is an abbreviation for Arena Pharmaceuticals Development. Certaimn statements in this press releaseare forward-looking statements that involver a number of risk s and uncertainties. Such forward-looking statements includew statements about theBLOOM results; the advancement, therapeutic indication, tolerability, safety, selectivity and efficact of lorcaserin; the FDA's guidance, process and requirements; the potential of the lorcaserin Phase 3 program and its resultsz to meet the FDA's approval including with regard to assessingt the risk of developing valvulopathy; the approvapl of lorcaserin for marketing; lorcaserin'sz partnering, commercial and other potential; the protocol, scope, enrollment and other aspects of the lorcaserin trials; futurd activities, results and announcements relating to including the BLOSSOM results, the submissiohn of an NDA for lorcaserin and the submission of the BLOOM-DMj results as a supplement to the NDA; the potentiall of lorcaserin in managingf weight, improving health and generating patient the impact of weighgt loss on health, including improvinb co-morbidities and providing other medically significant lorcaserin's patent coverage; and Arena's strategy, internal and partnered programs, and ability to develol compounds and commercialize drugs.
For such statements, Arena claimd the protection of the Privatr Securities Litigation Reform Actof 1995. Actual events or results may differ materiallyfrom Arena's expectations. Factore that could cause actual resulta to differ materially fromthe forward-looking statements but are not limites to, Arena's ability to obtaibn additional funds; the timing, success and cost of Arena'z lorcaserin program and othert of its research and development results of clinical trialws or preclinical studies may not be predictivd of future results; clinica trials and studies may not proceed at the time or in the manne r Arena expects or at all; Arena's abilityg to partner lorcaserin or other of its compoundz or programs; the timing and ability of Arena to receiv e regulatory approval for its drug candidates; Arena's abilit to obtain and defend its and the timing and receipt of payments and if any, from Arena's Additional factors that could causwe actual results to diffe materially from those statedc or implied by Arena's forward-looking statements are disclosed in Arena'sx filings with the Securities and Exchange These forward-looking statements represent Arena's judgmenty as of the time of this release.
Arena disclaimes any intent or obligation to updatethesse forward-looking statements, other than as may be required under applicable law. Jack Lief President and Chietf Executive Officer Cindy McGese Senior Communications AssociateArena Inc. 858.453.7200, ext. 1479 SOURCE Arenas Pharmaceuticals, Inc.
Previously announced BLOOM data demonstrated that lorcaserin was highly achieving statistical significance on allthrewe co-primary efficacy endpoints, and was very well tolerated. The BLOOnM results also satisfy the efficacy requirement in the most recenft US Food andDrug Administration, or FDA, drafrt guidance for the development of drugs for weightg management. "These data provide reason for new optimism for the millionsx of people who struggle with managing theidr weight and are in needof novel, well tolerates treatments to help improve their overall health," said Steven R. Smithh , M.D.
, Co-Principal Investigator and Professor and Assistant Director for Clinical Research at the Penningtonm BiomedicalResearch Center. "Lorcaserin's positive impact on multipl secondary measures has important implications forimprovinh co-morbidities associated with excess weight and furthere demonstrates the medically significant benefits of 5% or more weigh loss, a mark two-thirds of the lorcaserin patient s who completed the BLOOM trial achieved." "Given the positivre lorcaserin BLOOM results, we are focused on partnering effortsx and realizing lorcaserin's significant commercial potential," stated Jack Lief, Arena's Presidenyt and Chief Executive Officer.
In addition to supporting the previously announcex results on allthree co-primart endpoints on an last observation carried forward basis, the data presenter today demonstrated strong efficacy in patients who completed one year of treatmen according to the trial's protocol. In the per protocol nearly two-thirds (66.4%) of lorcaserin patients lost atleast 5% of theidr weight compared to 32.1% of patients on placebo and over one-third (36.2%) of lorcaserin patientss lost at least 10% of their weight comparexd to 13.6% for placebo (p<0.0001). The averag e weight loss in this populationwas 17.9 pounds in the lorcaserih group, compared to 7.4 pound s in the placebo group.
Patients randomized to remain on lorcaseri for Year 2 maintained a significantly greater amount of weight loss compared to the lorcaserib patients who switched to placeb at Week 52 in boththe ITT-LOCc and per protocol populations. New data demonstrate that treatmentf with lorcaserin over one year was associated with highlg significant improvements compared to placebo in multiple secondary endpoints associated withcardiovascular risk, -- Blood Pressure: systolic blood pressure, diastolic blood pressurs and heart rate -- Lipids: total cholesterol, LDL cholesteropl and triglycerides -- Glycemic fasting glucose, fasting insulin and insulin resistance -- Inflammator Markers of Cardiovascular high-sensitivity CRP and fibrinogen Qualitg of Life, as assessed by the Impact of Weightg Questionnaire - Lite, also improves to a significantly greater extent in the lorcaserin group than the placebo group at Week 52.
"We are please to present the BLOOM data in a scientific Inthis trial, lorcaserin helped patients rapidly lose weight and keep it off in a well-tolerateds manner," said William R. Shanahan , M.D., Arena's Vice President and Chierf Medical Officer. "We believed that lorcaserin's overall safety profile along with the significantt improvements seen in important secondary endpointsx associated with cardiovascular risk will be supportives of the approval We look forward to announcinv our BLOSSOM data in September and completing our NDA submissiom by the end ofthe year.
" Lorcaseri was very well Discontinuation rates for adverse events were similar in the lorcaserihn and placebo groups for Year 1 and Year 2 (7.1 vs. 6.7% and 3.0% vs. 3.0%, respectively). In additiob to the previously announcedtolerability data, today's presentation also reportede that lorcaserin demonstrated no increase in depressionb or suicidal ideation compared to placebo. Depression adverse events were measured using a Standard MedDRA Query for adverse eventt terms related todepression depression, depressed mood, crying, decreased interest, Overall, the rate of depression-relatef events was low and ratew were comparable in patients who took lorcaserin and Suicidal ideation was prospectively evaluated by administration of the Beck Depressionj Inventory-II.
Overall, the rate of suicidak ideation was low and simila numbers of patients on lorcaserin and placeboi reported suicidal thoughts during Year 1 andYear 2. Usinfg an LOCF analysis for each year, the assessment of echocardiogramds performed at baseline and aftert patientscompleted 6, 12, 18 and 24 monthsw of dosing indicated that lorcaserin was not associatexd with valvular insufficiency: during two years of use, rateas of change in individual regurgitang scores and the development of FDA-defined valvulopathh (moderate or greater mitral insufficiency and/or mild or greater aorti insufficiency) were similar between treatment Lorcaserin met the primary safety endpoint of no significant difference in ratesw of valvulopathy at 12 months.
Rates of valvulopathyg at 6, 12, 18 and 24 monthsd for lorcaserin versus placebowere 2.1% vs. 1.9% (p=0.88), 2.7% vs. 2.3% 2.9% vs. 3.1% (p=0.86) and 2.6% vs. 2.7% At 18 and 24 months, rates of valvulopathyh for lorcaserin patients crossing over to placeblwere 3.6% and 1.9%, respectively. In addition, similare numbers of mitral insufficiency shiftw and aortic insufficiency shifts in Year 1 and Year 2 were reportec for patients on lorcaserinand placebo. The FDA previously requested that Arena rule outa 1.5-fold or greaterd risk of valvulopathy with 80% power.
Assuminb similar results in Arena's final pivotal trial, BLOSSOM (Behavioral modification and LOrcaserin Second Study forObesityh Management), the integrated data set from the two trialsa will be more than sufficientlt large to meet this requirement. BLOOM, the first of three lorcaserin Phase3 trials, is a randomized, placebo-controlled trial involvinh 3,182 patients in approximately 100 sites in the US. The triap evaluated 10 mg of lorcaserin dosefd twice daily versus placebo overa two-year treatment periods in obese patients (Body Mass Index, or BMI, 30 to 45) with or without co-morbid conditions and overweight patients (BMI 27 to less than 30) with at leastt one co-morbid condition.
The triall did not include any dose titrationor run-in period. Patients were randomized in a 1:1 ratiio to lorcaserin or placeboat baseline. At Week 52, 856 patienta taking lorcaserinwere re-randomized in a 2:1 ratio to continus lorcaserin or to switch to placebo, and 697 patients on placebop were continued on placebo. Patients received echocardiogramsat screening, and at 6, 12, 18 and 24 months after initiating dosing in the patients with FDA-defined valvulopathy were excludeds from enrolling in the trial.
The Phased 3 program consists ofthree trials, BLOOM, BLOSSOM and BLOOM-DMM (Behavioral modification and Lorcaserin for Overweight and Obesith Management in Diabetes Mellitus), and is plannerd to enroll a total of approximately 7,800 patients. BLOOM and BLOSSOM comprise the Phase 3 pivotaplregistration program. BLOSSOM has enrolled 4,008 patients and is evaluating 10 mg of lorcaserin dosed once or twicw daily versus placebo overa one-year treatment period in obese patients with or withoutr co-morbid conditions and overweight patients with at least one co-morbid condition at abou 100 sites in the US.
BLOOM-DMM is expected to completwe enrollment around the end of June and is evaluatingv 10 mg of lorcaserin dosedr once or twice daily versuse placebo overa one-year treatment period in obese and overweightr patients with type 2 diabetes at about 60 sites in the US. Approximatelty 600 patients are expected to be enrolled in which is planned as a supplement to thelorcaserin NDA. A standardizecd program of moderate diet and exerciswe guidance is included in the Phase3 program.
The program's hierarchicall y ordered co-primary efficacy endpoints are: the proportion of patient achieving 5% or greater weight loss aftere12 months, the difference in mean weight loss compared to placebo after 12 months, and the proportioh of patients achieving 10% or greater weightg loss after 12 months. Arena is also studyintg several keysecondary endpoints, including changes in seru m lipids, markers of inflammation and insulib resistance, and in the BLOOM-D trial, other indicators of glycemic control. In BLOSSOMk and BLOOM-DM all patients will receive echocardiogramzsat baseline, at month 6, and at the end of the studt to assess heart valve function over time.
In contrastf to the BLOOM trial, however, there are no echocardiographicf exclusion criteria for entry into thes trials and there is no monitoring by anindependent board. Lorcaserin is a noveol single agent that represents the first in a new class of selective serotonin 2Creceptor agonists. The serotonin 2C receptot is located in areas of the brainh involved in the control of appetiteand metabolism, such as the Stimulation of this receptor is strongly associatesd with feeding behavior and satiety.
Lorcaserin is currently being evaluates in a Phase 3 program expected to enrololapproximately 7,800 patients and potentially represents a targeteed treatment option for the millions of patients who need to bettere manage their weight. Arena has patents that cover lorcaserin in the US andothef jurisdictions, which in most cases are capable of continuingf into 2023 without taking into account any patenrt term extensions or other exclusivity Arenq might obtain. The National Institutes of Health reported in 2007 thatabout 65% of US adultxs are overweight or obese.
Medical and related costs of obesity to the USare $123 billion per year accordintg to a 2005 report by the Internationa l Diabetes Federation. Studies have shownm that weight lossof 5% to 10% is medically significanty and results in meaningful improvementw in cardiovascular risk factors and a significant reductionm in the incidence of type 2 diabetes. Diet and exercise should form the basis of healthy weight but pharmaceutical treatment options for obesity are currentlg limited for the many patientw that require additional help in achieving and maintaining medically importantweigh loss.
The FDA draft guidance document for developing products for weighyt management dated February 2007 provides recommendations regarding the development of druges for the indication of weight It contains two alternate efficacy only one of which needs to be metfor approval. The guidancw provides that, in general, a producr can be considered effective for weight management if afterf one year of treatment either of thefollowing occurs: (1) the difference in mean weight loss between the active-product and placebo-treaterd groups is at least 5% and the differenced is statistically significant, or (2) the proportion of subjecte who lose greater than or equal to 5% of baselined body weight in the active-product group is at least 35%, is approximately double the proportiobn in the placebo-treated group, and the difference betweemn groups is statistically significant.
Arena is a clinical-stage biopharmaceutical company focusedon discovering, developing and commercializinf oral drugs in four major therapeutic areas: central nervous system, inflammatory and metabolixc diseases. Arena's most advanced drug candidate, lorcaserin, is being investigated in a Phasse 3 clinical trial program forweight Arena's broad pipeline of novel compounda target G protein-coupled receptors, an important class of validated drug and includes compounds being evaluated independently and with including Merck & Co., Inc., and Ortho-McNeil-Janssemn Pharmaceuticals, Inc. Arena Pharmaceuticals(R) and Arena(R) are registered service marks ofthe company.
"APD" is an abbreviation for Arena Pharmaceuticals Development. Certaimn statements in this press releaseare forward-looking statements that involver a number of risk s and uncertainties. Such forward-looking statements includew statements about theBLOOM results; the advancement, therapeutic indication, tolerability, safety, selectivity and efficact of lorcaserin; the FDA's guidance, process and requirements; the potential of the lorcaserin Phase 3 program and its resultsz to meet the FDA's approval including with regard to assessingt the risk of developing valvulopathy; the approvapl of lorcaserin for marketing; lorcaserin'sz partnering, commercial and other potential; the protocol, scope, enrollment and other aspects of the lorcaserin trials; futurd activities, results and announcements relating to including the BLOSSOM results, the submissiohn of an NDA for lorcaserin and the submission of the BLOOM-DMj results as a supplement to the NDA; the potentiall of lorcaserin in managingf weight, improving health and generating patient the impact of weighgt loss on health, including improvinb co-morbidities and providing other medically significant lorcaserin's patent coverage; and Arena's strategy, internal and partnered programs, and ability to develol compounds and commercialize drugs.
For such statements, Arena claimd the protection of the Privatr Securities Litigation Reform Actof 1995. Actual events or results may differ materiallyfrom Arena's expectations. Factore that could cause actual resulta to differ materially fromthe forward-looking statements but are not limites to, Arena's ability to obtaibn additional funds; the timing, success and cost of Arena'z lorcaserin program and othert of its research and development results of clinical trialws or preclinical studies may not be predictivd of future results; clinica trials and studies may not proceed at the time or in the manne r Arena expects or at all; Arena's abilityg to partner lorcaserin or other of its compoundz or programs; the timing and ability of Arena to receiv e regulatory approval for its drug candidates; Arena's abilit to obtain and defend its and the timing and receipt of payments and if any, from Arena's Additional factors that could causwe actual results to diffe materially from those statedc or implied by Arena's forward-looking statements are disclosed in Arena'sx filings with the Securities and Exchange These forward-looking statements represent Arena's judgmenty as of the time of this release.
Arena disclaimes any intent or obligation to updatethesse forward-looking statements, other than as may be required under applicable law. Jack Lief President and Chietf Executive Officer Cindy McGese Senior Communications AssociateArena Inc. 858.453.7200, ext. 1479 SOURCE Arenas Pharmaceuticals, Inc.
Monday, October 24, 2011
English bulldog held for ransom in Woodland found dead - OregonLive.com
ejyceh.wordpress.com
English bulldog held for ransom in Woodland found dead OregonLive.com By Lynne Terry, The Oregonian Cowlitz County Sheriff's OfficeJagger, an English Bulldog that was reported stolen from a Woodland, Wash., home, has been found dead next to train tracks. A beloved English bulldog that was snatched and held for ransom has ... Woodland dog 'held for ransom' found dead Police: Dead dog found in Kelso, may be one missing from Woodland Stolen dog found dead by railroad tracks |
Saturday, October 22, 2011
Sinclair Broadcast Group
omagyvoham.wordpress.com
The rating agency put the Hunt Valley company on anegatived outlook, meaning there are concerns its position coulf worsen. S&P cited sluggish ad spending in a recessioh andnonelection year, plus high debt risk for the The downgrade makes it more expensive for the companyt to borrow money. Sinclair SBGI) operates 58 TV stations acrosx the country but has also invested morethan $180 millio n in other assets, such as real estate, over the past two S&P analysts said. And they were concerned abour debt from those The ratio ofthe company’s debts to its earnings was 6.3 times as of March 31, according to S&P.
It wouldx need to bring that below 6 times to return toa BB- negativew rating. But S&P expects that ratio couldd hit 7 times laterthis year. Sinclair posted an $86 million loss in the first quarter ofthe year, largely on a $130 millionh non-cash charge. Its revenue fell 17 percent that quartere because of declining local and nationalad
The rating agency put the Hunt Valley company on anegatived outlook, meaning there are concerns its position coulf worsen. S&P cited sluggish ad spending in a recessioh andnonelection year, plus high debt risk for the The downgrade makes it more expensive for the companyt to borrow money. Sinclair SBGI) operates 58 TV stations acrosx the country but has also invested morethan $180 millio n in other assets, such as real estate, over the past two S&P analysts said. And they were concerned abour debt from those The ratio ofthe company’s debts to its earnings was 6.3 times as of March 31, according to S&P.
It wouldx need to bring that below 6 times to return toa BB- negativew rating. But S&P expects that ratio couldd hit 7 times laterthis year. Sinclair posted an $86 million loss in the first quarter ofthe year, largely on a $130 millionh non-cash charge. Its revenue fell 17 percent that quartere because of declining local and nationalad
Thursday, October 20, 2011
Downtown Staybridge Suites seeks receivership - The Business Journal of Milwaukee:
shelly-polymer.blogspot.com
SJ Properties Suites Buyco EHF, which includes an investor from Reykjavik, Iceland, filed the petitio Monday in Milwaukee County Circuit Judge Mel Flanagan scheduled a hearinhg for June 30 on a motionn to appoint Milwaukee attorney Seth Dizard as the Work stopped in Decembe r 2008 onthe high-rise at 1150 N. Waterf Street when the construction managet and developer DOC Milwaukeebecames insolvent, according to the receivershipp petition. The Icelandic investors said that in Novembert 2006 they provided an advanceof $17.4 million for a 120-room extended stay hotel and at leastf 18 luxury condos. The projecrt also received $13.
4 million in financing from a unit of in which in May was placed in receivershipo bythe FDIC. The Milwaukee receivership petitionj said the property on Water Street alreadyhas furniture, floorinvg and fixtures in the Staybridge portion of project. Liens againsyt the project total morethan $3.4 million, accordinb to the receivership petition. The largest lien s were filed by Milwaukee-area contractors and supplierdsUihlein Electric, , and Klein-Dickert. SJ Propertiex recently sued DOC Milwaukee and Economou Partnersin U.S. District Courty in Milwaukee claiming a fraudulent transfer of funds intendeed for the WaterStreet project.
SJ Properties Suites Buyco EHF, which includes an investor from Reykjavik, Iceland, filed the petitio Monday in Milwaukee County Circuit Judge Mel Flanagan scheduled a hearinhg for June 30 on a motionn to appoint Milwaukee attorney Seth Dizard as the Work stopped in Decembe r 2008 onthe high-rise at 1150 N. Waterf Street when the construction managet and developer DOC Milwaukeebecames insolvent, according to the receivershipp petition. The Icelandic investors said that in Novembert 2006 they provided an advanceof $17.4 million for a 120-room extended stay hotel and at leastf 18 luxury condos. The projecrt also received $13.
4 million in financing from a unit of in which in May was placed in receivershipo bythe FDIC. The Milwaukee receivership petitionj said the property on Water Street alreadyhas furniture, floorinvg and fixtures in the Staybridge portion of project. Liens againsyt the project total morethan $3.4 million, accordinb to the receivership petition. The largest lien s were filed by Milwaukee-area contractors and supplierdsUihlein Electric, , and Klein-Dickert. SJ Propertiex recently sued DOC Milwaukee and Economou Partnersin U.S. District Courty in Milwaukee claiming a fraudulent transfer of funds intendeed for the WaterStreet project.
Tuesday, October 18, 2011
Bravo to Fort Collins Symphony Orchestra - The Coloradoan
cahijisebi.wordpress.com
Bravo to Fort Collins Symphony Orchestra The Coloradoan Despite the lagging economy as well as the challenges of having to move out of the Lincoln Center for a year while it was being renovated, the FCSO is holding its own with a sold-out season-opening concert and record ticket sales as they return to ... |
Sunday, October 16, 2011
Developer scraps S.F. Whole Foods project because of city fees - Kansas City Business Journal:
doqujamup.wordpress.com
Project manager Mark Brennan said the family development business would have had to paybetween $5 million and $6 millioh in city fees just to pull permites on the development, which was to includre 62 apartments and a 34,000 squaree foot Whole Foods. The development fees cover everythingf from an affordable housing to San Francisco Unifieed School District to the PublicUtilities Commission. “It’s prohibitive,” said "We just took a look at the market and our own budgey and every time we came up with a the feeswere prohibitive.
” Brennan blamedd the city's rigorous 32-month entitlement process that starte d in February of 2006, when the economuy was roaring, and did not end until Octoberd 2008, when the global financial crisie was in full swing. “This project should have started ayear ago. It’s he said “If this had startexd when it was supposed to stary we would have already turned the shell over toWholw Foods. We would be But the financing will be difficul t toget now.
” Brennan said his famil y is in talks with Whole Foods about possibly buildintg out a smaller specialty grocerhy store in the existing 23,600 square foot but that no deal has been The building was home to Cala Foods until the storre closed in May of 2006.
Project manager Mark Brennan said the family development business would have had to paybetween $5 million and $6 millioh in city fees just to pull permites on the development, which was to includre 62 apartments and a 34,000 squaree foot Whole Foods. The development fees cover everythingf from an affordable housing to San Francisco Unifieed School District to the PublicUtilities Commission. “It’s prohibitive,” said "We just took a look at the market and our own budgey and every time we came up with a the feeswere prohibitive.
” Brennan blamedd the city's rigorous 32-month entitlement process that starte d in February of 2006, when the economuy was roaring, and did not end until Octoberd 2008, when the global financial crisie was in full swing. “This project should have started ayear ago. It’s he said “If this had startexd when it was supposed to stary we would have already turned the shell over toWholw Foods. We would be But the financing will be difficul t toget now.
” Brennan said his famil y is in talks with Whole Foods about possibly buildintg out a smaller specialty grocerhy store in the existing 23,600 square foot but that no deal has been The building was home to Cala Foods until the storre closed in May of 2006.
Thursday, October 13, 2011
Study: Charitable giving down in 2008 - New Mexico Business Weekly:
http://oiaweb.com/vp/62472.html
According to an annual report released Wednesdayu bythe , U.S. giving in 2008 totaler $307.65 billion, down about 2 percentr from 2007’s record total of $314.07 billion. When adjustef for inflation, the drop is 5.7 The reduction is the first inthe survey’s 52-yeard history caused by economic A slight decline in 1987 is attributed to changes in tax laws. This year could see a steeper declinse due to a variety of factorss including proposed federal limits on householdd charitabledeductions , increased savings rates and the generaol economy, said Jimmie Alford, founder of the , a nationall nonprofit consultant based in Seattle.
“It would not surprised me at all for givin g to be down on a nominal basisin 2009,” Alfore said. Alford said 2009 could bring a reduction in givingt of between 3 percentf and 5 percent inactual dollars. Individuals accounterd for the majorityof giving, contributing 74.5 percent of all Foundations accounted for 13.4 bequests contributed 7.4 percent and corporationsz contributed the smallest amount worth 4.7 When adjusted for inflation, all major sourcex of giving reduced their contributions. Corporations cut back the lowering their giving by8 percent. About half of all corporate giftssare in-kind donations of productsa like food or software. Individual giving fell 6.
3 percenf when adjusted for inflation. It is the largest drop-oft among individuals in the survey’s history. Foundation giving fell by an inflation-adjusted 0.8 percenr in 2008. However, with the precipitous drop in the stoc k market and the way that foundations calculatde theirdistribution totals, Alford said he expects foundation givinhg to continue to deteriorate this For 20 years foundatiobn giving has risen dramatically, from $11.19 billion in 1988 to $41.22 billion in 2008, on an inflation-adjusted The drop in foundatiobn giving also likely signifies a reduction in the formatioj of new foundations.
“There will be fewer, I growth in family foundations as a reflection in the growth of the Alford said. Among giving recipients, only religious organizations and “public groups saw their donationss increaseduring 2008, according to the But those uses can be misleadin g as both of those segments contribute to other includingy human services. The steepest decline among recipientss was inhuman services, whicuh experienced a 15.9 percent reduction in inflation-adjusted The reduction is unusual, Alford because usually human servicwe agencies see an increase during recessions as donorss steer more money to basiv needs like food and housing.
Othetr steep declines were seen byhealth (10 arts (9.9 percent), education (9 percent) and the environment/animalz (9 percent). Altogether, giving as a portio n of the nation’s gross domestic productr remained steadyat 2.2 percent. The nonprofiy sector accounts for abourt 10 percent ofthe nation’s GDP and employs 18 million, most of whom work in educatio n and health care, accordingg to the Alford
According to an annual report released Wednesdayu bythe , U.S. giving in 2008 totaler $307.65 billion, down about 2 percentr from 2007’s record total of $314.07 billion. When adjustef for inflation, the drop is 5.7 The reduction is the first inthe survey’s 52-yeard history caused by economic A slight decline in 1987 is attributed to changes in tax laws. This year could see a steeper declinse due to a variety of factorss including proposed federal limits on householdd charitabledeductions , increased savings rates and the generaol economy, said Jimmie Alford, founder of the , a nationall nonprofit consultant based in Seattle.
“It would not surprised me at all for givin g to be down on a nominal basisin 2009,” Alfore said. Alford said 2009 could bring a reduction in givingt of between 3 percentf and 5 percent inactual dollars. Individuals accounterd for the majorityof giving, contributing 74.5 percent of all Foundations accounted for 13.4 bequests contributed 7.4 percent and corporationsz contributed the smallest amount worth 4.7 When adjusted for inflation, all major sourcex of giving reduced their contributions. Corporations cut back the lowering their giving by8 percent. About half of all corporate giftssare in-kind donations of productsa like food or software. Individual giving fell 6.
3 percenf when adjusted for inflation. It is the largest drop-oft among individuals in the survey’s history. Foundation giving fell by an inflation-adjusted 0.8 percenr in 2008. However, with the precipitous drop in the stoc k market and the way that foundations calculatde theirdistribution totals, Alford said he expects foundation givinhg to continue to deteriorate this For 20 years foundatiobn giving has risen dramatically, from $11.19 billion in 1988 to $41.22 billion in 2008, on an inflation-adjusted The drop in foundatiobn giving also likely signifies a reduction in the formatioj of new foundations.
“There will be fewer, I growth in family foundations as a reflection in the growth of the Alford said. Among giving recipients, only religious organizations and “public groups saw their donationss increaseduring 2008, according to the But those uses can be misleadin g as both of those segments contribute to other includingy human services. The steepest decline among recipientss was inhuman services, whicuh experienced a 15.9 percent reduction in inflation-adjusted The reduction is unusual, Alford because usually human servicwe agencies see an increase during recessions as donorss steer more money to basiv needs like food and housing.
Othetr steep declines were seen byhealth (10 arts (9.9 percent), education (9 percent) and the environment/animalz (9 percent). Altogether, giving as a portio n of the nation’s gross domestic productr remained steadyat 2.2 percent. The nonprofiy sector accounts for abourt 10 percent ofthe nation’s GDP and employs 18 million, most of whom work in educatio n and health care, accordingg to the Alford
Tuesday, October 11, 2011
Startup leverages gadgets to chip away at golf market - Boston Business Journal:
kdrummondbs37.blogspot.com
AccelGolf, a participant in the recently establishef TechStars program for startupsin Cambridge, is developing softward to help golfers advance their games by keeping trac of their progress on the links via iPhones and “We’re providing a service ... to golferzs specifically, which allows them to really drill down into their game to find out wheree they needto improve,” said William Sulinski, co-foundeer of Portland, Maine-based mCaddie Inc., which does business as AccelGolf. Consumerw who own one of Apple Inc.
’s AAPL) iPhones or ’s RIMM) BlackBerry devices can download AccelGolf’sd application for use on the That application enables golfer s to track their games using adigital scorecard, whichj lets players store every game they have ever playefd online and compare themselves against other playerws with similar handicaps. Additionally, the software uses GPS technology to track distances onthe course, enablingy golfers to gauge their distances to the fairway or the pin, for The startup is at work on a revamped product that can track every shot and communicate “what club you should use baser on your hitting patterns,” Sulinskoi said.
Though AccelGolf is from Maine, it is currently one of the nine companies taking part in the localTechStars program, whichg officially launched in May. The prograk provides a select group of startups with upto $16,000 in seed funding and threer months of close guidance with mentors from the high-tec industry. AccelGolf was chosen from a pool of aboug300 applicants, said Shawn executive director of TechStars in Cambridge. “j was really impressed with the quality of what they had alreadyy been able to producsfor super-short money,” he said. John a lecturer at in Wellesley and the former CEOof , said the technologyt and others like it could be a big hit amongf avid golfers.
“It appeals to the self-expressive aspect of the golf game,” he said. To AccelGolf, which is nine months old, has raisesd about $50,000 through various grantws and businesscompetition awards, and its foundersx have invested about $25,000 of their own money, Sulinski said. The startup is currently looking for an angel investmen ofabout $100,000. Currently, AccelGolf’s application is free to But the company plans eventually to charger a quarterly subscription fee ofarounde $35 for golfers who use it ever day. There are about 28.6 million golfers in the United according tothe .
Sulinskk said his company only needsw a fraction of that marketg for his startup to turna profit. But there is plenty of competition. Several devicesd containing GPS technologies are availabld to golfers forbetween $200 and Sulinski, however, said the low-cost model of piggybackinhg on existing gadgets will make AccelGolf’s product more
AccelGolf, a participant in the recently establishef TechStars program for startupsin Cambridge, is developing softward to help golfers advance their games by keeping trac of their progress on the links via iPhones and “We’re providing a service ... to golferzs specifically, which allows them to really drill down into their game to find out wheree they needto improve,” said William Sulinski, co-foundeer of Portland, Maine-based mCaddie Inc., which does business as AccelGolf. Consumerw who own one of Apple Inc.
’s AAPL) iPhones or ’s RIMM) BlackBerry devices can download AccelGolf’sd application for use on the That application enables golfer s to track their games using adigital scorecard, whichj lets players store every game they have ever playefd online and compare themselves against other playerws with similar handicaps. Additionally, the software uses GPS technology to track distances onthe course, enablingy golfers to gauge their distances to the fairway or the pin, for The startup is at work on a revamped product that can track every shot and communicate “what club you should use baser on your hitting patterns,” Sulinskoi said.
Though AccelGolf is from Maine, it is currently one of the nine companies taking part in the localTechStars program, whichg officially launched in May. The prograk provides a select group of startups with upto $16,000 in seed funding and threer months of close guidance with mentors from the high-tec industry. AccelGolf was chosen from a pool of aboug300 applicants, said Shawn executive director of TechStars in Cambridge. “j was really impressed with the quality of what they had alreadyy been able to producsfor super-short money,” he said. John a lecturer at in Wellesley and the former CEOof , said the technologyt and others like it could be a big hit amongf avid golfers.
“It appeals to the self-expressive aspect of the golf game,” he said. To AccelGolf, which is nine months old, has raisesd about $50,000 through various grantws and businesscompetition awards, and its foundersx have invested about $25,000 of their own money, Sulinski said. The startup is currently looking for an angel investmen ofabout $100,000. Currently, AccelGolf’s application is free to But the company plans eventually to charger a quarterly subscription fee ofarounde $35 for golfers who use it ever day. There are about 28.6 million golfers in the United according tothe .
Sulinskk said his company only needsw a fraction of that marketg for his startup to turna profit. But there is plenty of competition. Several devicesd containing GPS technologies are availabld to golfers forbetween $200 and Sulinski, however, said the low-cost model of piggybackinhg on existing gadgets will make AccelGolf’s product more
Sunday, October 9, 2011
Louisville-area stocks among good buys as market claws its way back - Business First of Louisville:
fabyqyku.blogspot.com
In aisle three, for example, , the Louisville-based health-insurancew giant, has a price-earnings ratio of 6.5, meanintg its stock price is 6.5 times the company’s annualk earnings per share. That’s far below the market’s historidc aggregate P-E ratio of 15, or the 40-plu ratios at the height of 1990s bull On Wednesday, Humana was trading just belowa $30 per share, or 40 perceny below its 52-week high of $51 per share. Over in aisls five, there’s with a P-E ratio of trading at about $23 per share, 35 percengt off its 52-week high of $35.45 per shard even after reporting a significant increasein first-quartert net income.
The Dow Jones Industrial Average has rebounded abou t 30 percentsince first-quarter lows after precipitous fallzs not seen since the Great “Investors are coming back,” said Russ Ray, professot of finance at the ’s College of “Stocks are incredibly Ray said. “People are seeing that there are some very good companieeswith P-E ratios beaten down.” He added that he wouldn’ty be surprised if the stock market hasn’rt bottomed out “and we claw our way back.
” Ray attributex the rising market to more companied reporting surprisingly good earnings, or at leasty losses that weren’t as severe as Two Louisville-based companies — and , reported first-quarter earnings, Ray noted. On Tuesday, Kindrecd reported that first-quarter net income rose 55 percenr from ayear earlier, to $22.8 million from $14.y7 million. Texas Roadhouse reported that first-quarter net income rose 11 percent fromlast year, to $14.34 million from $12.9 million. Ray addef that, while there are glimmers of aneconomiv turnaround, the financial sector stillo is plagued by troubled assetws that are the residu of the housing bust and the subprimer mortgage fiasco.
National and super-regional bank executives are awaitinf final details ofthe ’s Public-Private Investment Program, which is designeds to value those then sell them to private investors. Results of the federall “stress test” of the nation’s 19 largesf banks were scheduled to be releasefd afterBusiness First’s press The problem is that administrators don’t know how to valuse them because of the complexity of some Ray said.
It will take a long time to sort throughy collateralized debt obligations and the underlying tranchesw of good andbad mortgages, unregulated credit default swaps and other hedging said Ray, who has writtehn extensively about derivatives. Untik those questionable loans and investments are removes frombalance sheets, bank executives don’t want to lend “even those with large (Troubled Assets Relief Program) infusions from Treasury.” A boosyt from an unlikely source? Another complicationb is that the $830 billionn American Recovery and Reinvestmeng Act will take untilp 2010 to be fulluy injected into the he said.
In aisle three, for example, , the Louisville-based health-insurancew giant, has a price-earnings ratio of 6.5, meanintg its stock price is 6.5 times the company’s annualk earnings per share. That’s far below the market’s historidc aggregate P-E ratio of 15, or the 40-plu ratios at the height of 1990s bull On Wednesday, Humana was trading just belowa $30 per share, or 40 perceny below its 52-week high of $51 per share. Over in aisls five, there’s with a P-E ratio of trading at about $23 per share, 35 percengt off its 52-week high of $35.45 per shard even after reporting a significant increasein first-quartert net income.
The Dow Jones Industrial Average has rebounded abou t 30 percentsince first-quarter lows after precipitous fallzs not seen since the Great “Investors are coming back,” said Russ Ray, professot of finance at the ’s College of “Stocks are incredibly Ray said. “People are seeing that there are some very good companieeswith P-E ratios beaten down.” He added that he wouldn’ty be surprised if the stock market hasn’rt bottomed out “and we claw our way back.
” Ray attributex the rising market to more companied reporting surprisingly good earnings, or at leasty losses that weren’t as severe as Two Louisville-based companies — and , reported first-quarter earnings, Ray noted. On Tuesday, Kindrecd reported that first-quarter net income rose 55 percenr from ayear earlier, to $22.8 million from $14.y7 million. Texas Roadhouse reported that first-quarter net income rose 11 percent fromlast year, to $14.34 million from $12.9 million. Ray addef that, while there are glimmers of aneconomiv turnaround, the financial sector stillo is plagued by troubled assetws that are the residu of the housing bust and the subprimer mortgage fiasco.
National and super-regional bank executives are awaitinf final details ofthe ’s Public-Private Investment Program, which is designeds to value those then sell them to private investors. Results of the federall “stress test” of the nation’s 19 largesf banks were scheduled to be releasefd afterBusiness First’s press The problem is that administrators don’t know how to valuse them because of the complexity of some Ray said.
It will take a long time to sort throughy collateralized debt obligations and the underlying tranchesw of good andbad mortgages, unregulated credit default swaps and other hedging said Ray, who has writtehn extensively about derivatives. Untik those questionable loans and investments are removes frombalance sheets, bank executives don’t want to lend “even those with large (Troubled Assets Relief Program) infusions from Treasury.” A boosyt from an unlikely source? Another complicationb is that the $830 billionn American Recovery and Reinvestmeng Act will take untilp 2010 to be fulluy injected into the he said.
Friday, October 7, 2011
San Francisco Marriott Fisherman's Wharf Hotel Announces Alcatraz Package - MarketWatch (press release)
framptongeqeaqu1461.blogspot.com
San Francisco Marriott Fisherman's Wharf Hotel Announces Alcatraz Package MarketWatch (press release) The hotel and attraction package comes with deluxe accommodations at the hotel and two adult tickets for the cruise. The cruise on San Francisco Bay to Alcatraz Island will captivate you. Alcatraz is infamous for being the former federal prison for ... |
Wednesday, October 5, 2011
Nozzle Nolen Offering IPM Pest Control Services in Florida - AddPR.com (press release)
qalymeled.wordpress.com
Nozzle Nolen Offering IPM Pest Control Services in Florida AddPR.com (press release) Nozzle Nolen, offering pest control services in Florida for six decades, applies Integrated Pest Management (IPM), an effective and environmentally sensitive approach to controlling bugs and pests. Th West Palm Beach, FL 05 October 2011 : Nozzle Nolen, ... |
Monday, October 3, 2011
General Motors bankruptcy brings big gamble by Obama - Denver Business Journal:
erofeyporgrinin.blogspot.com
But the move alreadg has its skeptics. GM, once the world’s biggest auto maker, setting up a scenarioi under whichthe U.S. government will become GM’s largest shareholder. . “The only thing it makes cleaf is that the government is firmly in the businesds of running companies usingtaxpayer dollars,” said U.S. Houses GOP leader John Boehner. “Does anyone really believee that politicians and bureaucrats in Washington can successfully steef a multinational corporation to economicvitality ? It’s time for the administration to fully explain what the exit strategy is to get the U.S.
governmenf out of the board room once and for The government will own some 60 percentt of arevamped GM. Its ownershi p stake will give government officials more powee to name members of theGM board. But . And no one'd overjoyed at the investment. "We are acting as reluctantt shareholders," Obama said. "What I have no interesrt in doing isrunning GM." Instead of having politician taking an active role, the presideny said, a professional management team would lead GM as it works through bankruptcy and builds a more viable companh for the future.
“The federakl government will refrain from exercising its rightes as a shareholder in all but the most fundamentalkcorporate decisions,” Obama said. “When a difficulrt decision has to be made on matters like whered to open a new plant or what type of new car to thenew GM, not the United Statesx government, will make that decision. “In short, our goal is to get GM back on its takea hands-off and get out quickly,” he said. But that may prove to be quit e a challenge with as much governmentr money asis involved.
Brucew Belzowski, associate director of the Automotive Analysis Division at the Universityt of Michigan TransportationResearch Institute, told bizjournalws in a telephone interview: "If they had a it would be a short period of The longer that it stretches out the more of a political liability it becomes.” And there will be plenty of watchdogs alert for any government interferences in day-to-day GM operations. “We will expose and fighft any counterproductive influenceby government, unions or politicians over decisionw that should be left to management,” said Presidentg and CEO Tom Donohue.
“Andd we will continually insist that government reduce and eliminate its ownershi p stake as soonas possible.” It will take time befores the government is able to extricate itselc from such a large stake in the It could take more than a year beforwe GM emerges once more as a publiclu traded company, and shares in the company will have to rise high enougnh to make selling them profitable. "This is a question of years, not months," said GM CEO Fritz Henderson.
But the move alreadg has its skeptics. GM, once the world’s biggest auto maker, setting up a scenarioi under whichthe U.S. government will become GM’s largest shareholder. . “The only thing it makes cleaf is that the government is firmly in the businesds of running companies usingtaxpayer dollars,” said U.S. Houses GOP leader John Boehner. “Does anyone really believee that politicians and bureaucrats in Washington can successfully steef a multinational corporation to economicvitality ? It’s time for the administration to fully explain what the exit strategy is to get the U.S.
governmenf out of the board room once and for The government will own some 60 percentt of arevamped GM. Its ownershi p stake will give government officials more powee to name members of theGM board. But . And no one'd overjoyed at the investment. "We are acting as reluctantt shareholders," Obama said. "What I have no interesrt in doing isrunning GM." Instead of having politician taking an active role, the presideny said, a professional management team would lead GM as it works through bankruptcy and builds a more viable companh for the future.
“The federakl government will refrain from exercising its rightes as a shareholder in all but the most fundamentalkcorporate decisions,” Obama said. “When a difficulrt decision has to be made on matters like whered to open a new plant or what type of new car to thenew GM, not the United Statesx government, will make that decision. “In short, our goal is to get GM back on its takea hands-off and get out quickly,” he said. But that may prove to be quit e a challenge with as much governmentr money asis involved.
Brucew Belzowski, associate director of the Automotive Analysis Division at the Universityt of Michigan TransportationResearch Institute, told bizjournalws in a telephone interview: "If they had a it would be a short period of The longer that it stretches out the more of a political liability it becomes.” And there will be plenty of watchdogs alert for any government interferences in day-to-day GM operations. “We will expose and fighft any counterproductive influenceby government, unions or politicians over decisionw that should be left to management,” said Presidentg and CEO Tom Donohue.
“Andd we will continually insist that government reduce and eliminate its ownershi p stake as soonas possible.” It will take time befores the government is able to extricate itselc from such a large stake in the It could take more than a year beforwe GM emerges once more as a publiclu traded company, and shares in the company will have to rise high enougnh to make selling them profitable. "This is a question of years, not months," said GM CEO Fritz Henderson.
Saturday, October 1, 2011
High-deductible plans causing issues for health care providers - The Business Journal of the Greater Triad Area:
aryrej.wordpress.com
The plans come with a deductible of anywherdefrom $1,150 to $5,800 that allows employerxs and enrollees to keep theif premiums down. Many of the plans are tied to healthh savingsaccounts (HSAs) that employers or patients can fund with tax-deductible deposits to help pay those out-of-pocket costs. But doctorzs are seeing that, given the troubled patients are paying bills and buying necessitiexs before they fundtheir accounts. It’s creatingt a new class of patient: one who’sd insured but can’t afford up-fronf costs before coverage kicks in.
Fran Sembert, director of managede care for Greensboro-based multispecialty group EaglwePhysicians & Associates, said insurancew companies won’t allow doctors to collecf on high deductibles until the insurer fullgy processes the claim, which can take 30 to 45
The plans come with a deductible of anywherdefrom $1,150 to $5,800 that allows employerxs and enrollees to keep theif premiums down. Many of the plans are tied to healthh savingsaccounts (HSAs) that employers or patients can fund with tax-deductible deposits to help pay those out-of-pocket costs. But doctorzs are seeing that, given the troubled patients are paying bills and buying necessitiexs before they fundtheir accounts. It’s creatingt a new class of patient: one who’sd insured but can’t afford up-fronf costs before coverage kicks in.
Fran Sembert, director of managede care for Greensboro-based multispecialty group EaglwePhysicians & Associates, said insurancew companies won’t allow doctors to collecf on high deductibles until the insurer fullgy processes the claim, which can take 30 to 45
Subscribe to:
Posts (Atom)